Literature DB >> 10069411

Induction of CD8+ T cell-mediated protective immunity against Trypanosoma cruzi.

Y Miyahira1, S Kobayashi, T Takeuchi, T Kamiyama, T Nara, J Nakajima-Shimada, T Aoki.   

Abstract

Trypanosoma cruzi was transformed with the Plasmodium yoelii gene encoding the circum-sporozoite (CS) protein, which contains the well-characterized CD8+ T cell epitope, SYVPSAEQI. In vivo and in vitro assays indicated that cells infected with the transformed T. cruzi could process and present this malaria parasite-derived class I MHC-restricted epitope. Immunization of mice with recombinant influenza and vaccinia viruses expressing the SYVPSAEQI epitope induced a large number of specific CD8+ T cells that strongly suppressed parasitemia and conferred complete protection against the acute T. cruzi lethal infection. CD8+ T cells mediated this immunity as indicated by the unrelenting parasitemia and high mortality observed in immunized mice treated with anti-CD8 antibody. This study demonstrated, for the first time, that vaccination of mice with vectors designed to induce CD8+ T cells is effective against T. cruzi infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069411     DOI: 10.1093/intimm/11.2.133

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  8 in total

1.  Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection.

Authors:  Eiji Takayama; Takeshi Ono; Elena Carnero; Saori Umemoto; Yoko Yamaguchi; Atsuhiro Kanayama; Takemi Oguma; Yasuhiro Takashima; Takushi Tadakuma; Adolfo García-Sastre; Yasushi Miyahira
Journal:  Int J Parasitol       Date:  2010-07-08       Impact factor: 3.981

2.  Transfection of Trypanosoma cruzi with host CD40 ligand results in improved control of parasite infection.

Authors:  Mustapha Chamekh; Vincent Vercruysse; Mohammed Habib; Maxime Lorent; Michel Goldman; Abdelmounaïm Allaoui; Bernard Vray
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge.

Authors:  Matthew H Collins; Julie M Craft; Juan M Bustamante; Rick L Tarleton
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

4.  Activation of natural killer T cells by alpha-galactosylceramide impairs DNA vaccine-induced protective immunity against Trypanosoma cruzi.

Authors:  Yasushi Miyahira; Masaharu Katae; Kazuyoshi Takeda; Hideo Yagita; Ko Okumura; Seiki Kobayashi; Tsutomu Takeuchi; Tsuneo Kamiyama; Yoshinosuke Fukuchi; Takashi Aoki
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

5.  Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection.

Authors:  Yasushi Miyahira; Yasuhiro Takashima; Seiki Kobayashi; Yasunobu Matsumoto; Tsutomu Takeuchi; Mutsuko Ohyanagi-Hara; Ayako Yoshida; Akihiko Ohwada; Hisaya Akiba; Hideo Yagita; Ko Okumura; Hideoki Ogawa
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

6.  Critical contribution of CD28-CD80/CD86 costimulatory pathway to protection from Trypanosoma cruzi infection.

Authors:  Yasushi Miyahira; Masaharu Katae; Seiki Kobayashi; Tsutomu Takeuchi; Yoshinosuke Fukuchi; Ryo Abe; Ko Okumura; Hideo Yagita; Takashi Aoki
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

7.  NK-lysin and its shortened analog NK-2 exhibit potent activities against Trypanosoma cruzi.

Authors:  Thomas Jacobs; Heike Bruhn; Iris Gaworski; Bernhard Fleischer; Matthias Leippe
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

8.  Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy.

Authors:  Masaharu Katae; Yasushi Miyahira; Kazuyoshi Takeda; Hironori Matsuda; Hideo Yagita; Ko Okumura; Tsutomu Takeuchi; Tsuneo Kamiyama; Akihiko Ohwada; Yoshinosuke Fukuchi; Takashi Aoki
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.